Friday, June 10, 2022 9:48:28 AM
COGT up 60% @ 7.97
New York Yankees and Duke Basketball
Recent COGT News
- Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/14/2026 10:20:59 PM
- Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress • GlobeNewswire Inc. • 05/12/2026 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 12:21:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 12:08:36 PM
- Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/05/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/23/2026 08:35:38 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:33:21 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:30:56 PM
- Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/21/2026 12:00:00 PM
- Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 • GlobeNewswire Inc. • 04/17/2026 12:00:00 PM
- Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) • GlobeNewswire Inc. • 04/01/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 01:30:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 01:30:12 AM
- FDA accepts Cogent’s drug filing for treatment of rare blood disorder • IH Market News • 03/16/2026 02:28:14 PM
- Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) • GlobeNewswire Inc. • 03/16/2026 12:00:00 PM
- Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting • GlobeNewswire Inc. • 02/28/2026 02:45:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 09:42:42 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/17/2026 09:03:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:12:20 PM
- Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/17/2026 01:00:00 PM
- Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting • GlobeNewswire Inc. • 02/10/2026 01:00:00 PM
- Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) • GlobeNewswire Inc. • 01/26/2026 01:00:00 PM
